Hollencrest Capital Management’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Hollencrest Capital Management’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-36	Closed	-$920	–	1064
2023 Q3	$920	Hold	36	–	–	﹤0.01%	975
2023 Q2	$943	Hold	36	–	–	﹤0.01%	1027
2023 Q1	$940	Hold	36	–	–	﹤0.01%	1023
2022 Q4	$988	Buy	+36	New	+$958	﹤0.01%	1012

Other funds holding FTXH

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Glenview Trust Louisville, Kentucky $6.37B AUM 23.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

OWA

Outlook Wealth Advisors Shenandoah, Texas $413M AUM 19.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hollencrest Capital Management's FTXH Position: Q4 2023 in Review

Hollencrest Capital Management sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q4 2023, closing a stake of 36 shares — an estimated $920 sold.

Hollencrest Capital Management first reported a position in FTXH in Q4 2022 and held it in 4 quarters. The position peaked at $988 in Q4 2022. 22 funds tracked by Wall St. Rank hold FTXH as of Q4 2023.

Hollencrest Capital Management reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q4 2023 after selling out during the quarter.
Hollencrest Capital Management sold 36 First Trust Nasdaq Pharmaceuticals ETF shares in Q4 2023, an estimated $920.
Hollencrest Capital Management first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and held it in 4 quarters.
Hollencrest Capital Management's First Trust Nasdaq Pharmaceuticals ETF position peaked at $988 in Q4 2022.
22 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q4 2023.

Based on Hollencrest Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.